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OBJECTIVES We examined the relationship between diabetes mellitus and outcomes after coronary artery
bypass graft (CABG) surgery in patients with severe left ventricular (LV) dysfunction.
BACKGROUND Although diabetes is associated with poor outcomes after CABG surgery among unselected
patients, the relationship between diabetes and mortality after CABG surgery among patients
with LV dysfunction is less certain.
METHODS Using data from The CABG Patch Trial, a study of implantable cardiac defibrillator therapy,
we analyzed 900 patients with ejection fraction ,0.36 who underwent CABG surgery from
1990 to 1996.
RESULTS Diabetics comprised 38% of the patients, and 48% of diabetics were prescribed insulin.
Diabetes was associated with hypertension, peripheral vascular disease, history of stroke,
clinical heart failure and rales on physical exam. Diabetics were at higher risk for postoperative
superficial sternal wound infection and renal failure. With an average follow-up time of 32 6
16 months, actuarial all-cause mortality 48 months after CABG surgery was 26% in diabetics
and 24% in nondiabetics (p 5 0.66, log-rank test). Diabetes was not associated with
long-term mortality in Cox multiple regression analyses. Actuarial re-hospitalization rates 48
months after CABG surgery were 85% in diabetics and 69% in nondiabetics (p 5 0.0001,
log-rank test). Diabetics had a 44% higher risk of re-hospitalization for any cause (p 5
0.0001) and a 24% higher risk of re-admission for cardiac causes (p , 0.05). Unexpectedly,
fewer arrhythmic events were found in diabetics.
CONCLUSIONS Diabetes was not a predictor of mortality after CABG surgery among patients with LV
dysfunction despite associated comorbidities. However, diabetes was associated with in-
creased postoperative complications and re-hospitalization. (J Am Coll Cardiol 2000;36:
1166–72) © 2000 by the American College of Cardiology
Diabetes is a risk factor for coronary artery disease (CAD)
and heart failure (1,2). Investigators have posited several
possible mechanisms for the association between diabetes
and heart disease, including abnormalities in lipid metabo-
lism, nitric oxide activity, platelet function, coagulation and
autonomic function (3–7).
Not only is diabetes a risk factor for CAD, but observa-
tional studies have also linked it with worse outcomes after
revascularization via coronary artery bypass graft (CABG)
surgery (8–13). The higher mortality among diabetics after
revascularization is felt to be consistent with more severe
atherosclerosis associated with diabetic heart disease, possi-
bly in the form of more diffuse distal CAD that continues to
jeopardize myocardium.
The association between diabetes and mortality after
CABG surgery among patients with left ventricular (LV)
dysfunction is less conclusive. Some studies that examined
patients with reduced LV ejection fractions (LVEFs) have
identified diabetes as a risk factor for mortality (9,14); others
have not (15–17). In this study we assessed the long-term
results of CABG surgery in diabetic patients with LV
dysfunction using data from a multicenter trial. We tested
two primary hypotheses: 1) among patients with LV dys-
function who undergo CABG, diabetes is an independent
predictor of mortality, both all-cause and cardiac; 2) diabe-
tes is a predictor of the risk of re-hospitalization, due to all
causes and cardiac causes.
METHODS
Data collection. We performed a cohort analysis of data
collected for The CABG Patch Trial, a randomized study of
prophylactic implantable cardiac defibrillators (ICDs) in
high risk coronary heart disease patients undergoing CABG
surgery from 1990 to 1996 (18). Criteria for inclusion in the
trial included the following: age less than 80 years, LVEF
less than 0.36 and an abnormal signal averaged electrocar-
diogram (ECG).
In the main trial, 71,855 patients were screened for
inclusion, and 900 patients were randomized and followed
for an average of 32 6 16 months. Patients were excluded
from the trial on the basis of the following: diabetes mellitus
with poor blood glucose control or recurrent infections,
history of sustained ventricular tachycardia or fibrillation,
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previous or concomitant aortic or mitral valve surgery,
concomitant cerebrovascular surgery, serum creatinine
greater than 3 mg per deciliter, emergency coronary bypass
surgery, noncardiovascular condition with expected survival
less than two years or inability to attend follow-up visits.
Nurse coordinators at the 37 clinical centers involved in
the trial ascertained whether patients had ever been diag-
nosed with diabetes and whether treatment included insu-
lin. In obtaining information about early postoperative
outcomes, need for mechanical support was defined as the
use of an intra-aortic balloon pump or LV assist device on
exit from the operating room, and renal failure was defined
as renal dysfunction severe enough to require hemodialysis
or peritoneal dialysis (19). After the index hospitalization
for CABG surgery, follow-up visits were scheduled every
three months. Data on hospitalizations included the reason
for hospitalization, whether for a cardiac problem and
whether a definite/probable myocardial infarction, conges-
tive heart failure or ventricular arrhythmias occurred during
the hospital stay. An independent events committee classi-
fied each death that occurred according to whether the
mechanism of death was cardiac in nature, for example, due
to arrhythmia, myocardial pump failure or cardiac procedure
(20).
Statistical analysis. We collected information on baseline
demographic, clinical, angiographic and intraoperative risk
factors for postoperative complications, long-term mortality
and re-hospitalization. We examined differences in baseline
variables between diabetic and nondiabetic patients via
chi-square tests, with a correction for continuity for dichot-
omous variables. From our candidate predictors for
mortality/morbidity, we used chi-square tests to select
independent variables for multiple logistic regression mod-
els of perioperative complications and log-rank tests to
select variables for Cox multiple regression models in the
case of long-term outcomes. We used backwards stepwise
regression, with mandatory inclusion of diabetes status, to
select models for parsimony. Diabetes status was repre-
sented via two separate models for each outcome—one
model in which all diabetics were grouped together and
another in which patients treated with insulin and those
treated with oral hypoglycemics or diet were grouped
separately. We used chi-square tests for nested models to
test whether the relationship between diabetes and outcome
significantly differed depending on the type of treatment for
diabetes. Kaplan-Meier curves were constructed to compare
unadjusted time to death or re-hospitalization between
diabetics and nondiabetics. All statistical tests were per-
formed to reject the null hypothesis at a nominal alpha level
of 0.05. All analyses were performed using SAS Version
6.12.
RESULTS
Patient characteristics. Among the 900 patients studied,
344 (38%) of the patients were diabetic at the time of
CABG surgery (Table 1); 48% of the diabetic patients were
treated with insulin. Average follow-up time was 31 6 17
months among diabetics and 32 6 16 months among
nondiabetics. Compared with patients without diabetes,
diabetics were more likely to be women, obese and less likely
to have a history of tobacco use. Hypertension, peripheral
vascular disease, history of stroke, clinical heart failure and
rales on physical exam were more prevalent among diabet-
ics. Diabetics and nondiabetics did not significantly differ in
their severity of angina, LVEF, presence of left main or
triple vessel disease or use of internal mammary artery grafts
as conduits. Mean LVEF was 0.27 6 0.06 in both diabetics
and nondiabetics. Before CABG surgery, diabetics were
more likely to be treated with angiotensin converting-
enzyme inhibitors, diuretics and digoxin and less likely to be
treated with beta-adrenergic blocking agents (Table 1).
Postoperative complications. In analyses of perioperative
complications, diabetes was associated with an increased
risk of superficial sternal wound infection and renal failure
requiring dialysis (Table 2). The odds of superficial sternal
wound infection were 3.31 times greater (p , 0.05) and the
odds of renal failure were 2.24 times greater (p , 0.05) for
diabetic patients than for patients without diabetes. There
was a trend toward higher risk for these outcomes among
patients treated with insulin than there was among patients
treated with oral hypoglycemic agents; however, chi-square
tests for the interaction between type of treatment and both
superficial sternal wound infection and renal failure were not
statistically significant. Insulin therapy was associated with
an increased use of mechanical support (intra-aortic balloon
pump or LV assist device). Neither deep sternal wound
infection nor pneumonia was associated with diabetes in
multivariable logistic regression models. There was an
increased risk of deep sternal wound infection and pneumo-
nia among ICD patients; there was no significant interac-
tion between ICD use and diabetes in regression models of
either outcome.
Mortality. There were 198 total deaths, 157 cardiac deaths
and 43 arrhythmic deaths. The actuarial total mortality rate
at 48 months after CABG surgery was 26% in diabetics and
24% in patients without diabetes (p 5 0.66, log-rank test;
Fig. 1). Cardiac and arrhythmic death rates were 19.4% and
6.1%, respectively, in diabetics and 20.7% and 6.9% in
patients without diabetes. Diabetes was not significantly
associated either with cardiac or arrhythmic mortality by
log-rank test.
Neither diabetes nor treatment with insulin was signifi-
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cantly associated with increased long-term mortality in Cox
multiple regression analyses (Table 3). Age, history of
stroke, clinical heart failure, history of previous CABG
surgery and body mass index .30 were independent,
significant predictors of long-term postoperative mortality
in diabetics and in nondiabetics. In analyses of cardiac
mortality, diabetes was not a significant predictor of the risk
of death due to any cardiac cause. There was a strong trend
toward less arrhythmic mortality among diabetics in multi-
ple regression analyses; however, it was not statistically
significant. As has been reported previously (18), defibril-
lator therapy had no effect on long-term mortality, nor was
there a significant interaction between defibrillator therapy
and diabetes.
Re-hospitalization. The actuarial rate of re-hospitaliza-
tion at 12 months was 54% among diabetics and 41%
among nondiabetics; the corresponding rates at 48 months
were 85% and 69%, respectively (p 5 0.0001, log-rank test;
Fig. 2). The elapsed time before 50% of the diabetic group
was hospitalized was 23.7 months; the corresponding time
among nondiabetics was 44.8 months. After adjustment for
other variables, diabetes was associated with a statistically
significant 44% increase in the relative risk of rehospitaliza-
tion (Table 4). Although there was a trend toward a higher
risk of re-hospitalization for patients treated with insulin
than there was for patients treated with oral agents or
nonpharmacologic therapy, tests for the interaction be-
tween type of diabetes treatment and re-hospitalization
were not statistically significant. Diabetes also was asso-
ciated with a 24% increase in the risk of re-admission for
cardiac reasons. For initial re-hospitalizations, the odds
that the admission was for noncardiac reasons were 48%
higher among diabetics than they were among nondia-
betics (Table 5). Re-hospitalization was less likely to be
due to arrhythmias among diabetics, and relatively fewer
Table 1. Baseline/Intraoperative Characteristics Among Patients With and Without Diabetes*
Variable
Diabetes
(n 5 344)
No Diabetes
(n 5 556) Odds Ratio p Value
Age . 65 (%) 47.7 51.1 0.87 0.355
Men (%) 75.3 89.9 0.34 0.001
Cardiovascular history
Hypertension (%) 66.9 48.0 2.18 0.001
Cholesterol .200 (%) 54.3 53.8 1.02 0.959
Smoking (%) 74.1 80.9 0.68 0.021
Peripheral vascular disease (%) 18.0 10.4 1.89 0.002
Stroke (%) 8.7 4.5 2.03 0.015
COPD (%) 14.9 15.0 0.99 1.000
Previous CABG surgery (%) 9.9 11.4 0.86 0.563
Heart failure
No heart failure (%) 34.6 60.6 Ref.
Class I/II (%) 32.0 20.8 2.69 0.001
Class III/IV (%) 33.4 18.6 3.14 0.001
Angina
No angina (%) 28.8 23.3 Ref.
Class I/II (%) 31.0 35.6 0.71 0.074
Class III/IV (%) 40.1 41.1 0.79 0.214
Physical findings
Body mass index .30 (%) 39.5 23.9 2.08 0.001
Rales (%) 29.1 18.7 1.78 0.001
LVEF
#0.20 (%) 16.3 15.7 Ref.
0.21 to 0.30 (%) 57.6 53.8 1.03 0.961
.0.30 (%) 26.2 30.6 0.82 0.424
LVEDP .12 mm Hg (%) 82.0 79.7 1.16 0.515
Left main disease (%) 22.0 21.0 1.06 0.788
Triple vessel disease (%) 55.2 55.2 1.00 1.000
Use of IMA graft (%) 58.4 63.9 0.80 0.120
ICD group (%) 47.1 51.1 0.85 0.274
ACEI (%) 59.6 48.2 1.59 0.001
Diuretic (%) 61.9 41.4 2.31 0.001
Digoxin (%) 43.9 31.5 1.70 0.001
All three (%) 26.8 17.1 1.96 0.001
Beta-blocker therapy (%) 25.6 32.7 0.71 0.028
*Data were less than the full 900 observations for the following comparisons: cholesterol (n 5 245 for patients with diabetes, n 5 400 for patients without diabetes), smoking
(n 5 344, 555), COPD (n 5 343, 552), history of CABG surgery (n 5 344, 555), heart failure (n 5 344, 553), angina (n 5 319, 523), LVEDP (n 5 267, 449), left main disease
(n 5 318, 515).
ACEI 5 angiotensin converting-enzyme inhibitor; CABG 5 coronary artery bypass graft; COPD 5 chronic obstructive pulmonary disease; ICD 5 implantable cardiac
defibrillator; IMA 5 internal mammary artery; LVEDP 5 left ventricular end-diastolic pressure; LVEF 5 left ventricular ejection fraction; Ref. 5 reference.
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ventricular arrhythmias occurred during hospitalization
of patients with diabetes (Table 5).
DISCUSSION
In a cohort study of 900 patients in The CABG Patch Trial,
we tested two hypotheses of the link between diabetes and
outcomes after CABG surgery: 1) among patients with LV
dysfunction who undergo CABG, diabetes is an indepen-
dent predictor of mortality, both all-cause and cardiac; and
2) diabetes is a predictor of the risk of rehospitalization, due
to all causes and cardiac causes. Our study sample comprised
344 diabetics and 556 nondiabetics with low ejection
fraction (,0.36); approximately half of the patients had
clinical heart failure, and 198 died during the follow-up
period. Half the patients in the study received ICD therapy,
but ICD therapy had no effect on survival. Contrary to our
first hypothesis, the long-term risk of death after CABG
surgery was not significantly different for diabetics com-
pared with nondiabetics, despite higher rates of comorbidi-
ties such as hypertension, heart failure, peripheral vascular
disease and history of stroke among diabetics. However,
diabetes was associated with a higher risk of re-
hospitalization, including those for cardiac reasons.
Comparisons with other studies. Previous studies have
included diabetes as an explanatory variable for mortality
after CABG surgery among patients with reduced LV
function with varying results. As part of a larger study of
CABG surgery in diabetics, Morris and colleagues (9)
included approximately 870 patients with ejection fraction
#0.40, of whom about 27% were diabetic. Five-year mor-
tality was 34% among diabetics and 20% among nondiabet-
ics (p , 0.02). Trachiotis and colleagues (14) examined
Figure 1. Post-CABG survival by diabetes status (p 5 0.66, log-rank test).
Dotted line 5 no diabetes; solid line 5 diabetes.
Figure 2. Freedom from initial hospitalization post-CABG by diabetes
status (p 5 0.0001, log-rank test). Dotted line 5 no diabetes; solid line 5
diabetes.
Table 2. Multivariable Logistic Regression Models for Perioperative Complications by Outcome*
Variable Odds Ratio p Value Odds Ratio p Value
Mechanical support
Diabetes 1.208 0.3013 — —
Insulin — — 1.663 0.0236
Oral agent/diet — — 0.825 0.4342
LVEDP .12 mm Hg 1.820 0.0019 1.849 0.0016
Previous CABG 2.043 0.0083 2.130 0.0055
Superficial sternal wound infection
Diabetes 3.313 0.0176 — —
Insulin — — 4.701 0.0047
Oral agent/diet — — 2.095 0.2561
Deep sternal wound infection
Diabetes 1.737 0.3079 — —
Insulin — — 1.590 0.5072
Oral agent/diet — — 1.886 0.3186
ICD 6.397 0.0156 6.406 0.0155
Renal failure
Diabetes 2.241 0.0056 — —
Insulin — — 2.918 0.0015
Oral agent/diet — — 1.692 0.1553
Age .65 2.240 0.0084 2.260 0.0078
Previous CABG surgery 2.477 0.0127 2.523 0.0113
Pneumonia
Diabetes 0.967 0.9052 — —
Insulin — — 0.668 0.3418
Oral agent/diet — — 1.256 0.4892
ICD 2.130 0.0090 2.127 0.0092
*There were two separate logistic regression models for each outcome, one model in which all diabetics were grouped together and another in which patients treated with insulin
and patients treated with oral hypoglycemics or diet were grouped separately. Data were missing for models measuring mechanical support after bypass (n 5 715).
CABG 5 coronary artery bypass graft; ICD 5 implantable cardiac defibrillator; LVEDP 5 left ventricular end-diastolic pressure; — 5 not included.
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long-term survival after CABG surgery in 11,830 patients,
of whom 156 patients had ejection fraction ,0.25, and 588
patients had ejection fraction 0.25 to 0.34. In an analysis
inclusive of all the patients regardless of ventricular func-
tion, diabetes was associated with a 59% increase in the
relative risk of death (p , 0.0001). Gill and colleagues (15)
found that among 166 patients with ejection fraction
,0.31, during 4.75 years of follow-up, diabetes was not
associated with reduced survival after CABG surgery. Kaul
and colleagues (16) measured outcomes in 210 patients with
LVEF #0.20 who underwent CABG surgery at University
of Alabama from 1987 to 1992. During an average
follow-up of 43 months, diabetes was not significantly
associated with excess long-term mortality. Milano and
colleagues (17) studied outcomes among 118 patients with
ejection fraction #0.25, of whom 33% were diabetic.
Diabetes was not associated with long-term mortality in
single variable analyses.
Explanations for lack of mortality findings. The lack of a
relationship between diabetes and mortality after CABG
surgery in our analysis has multiple potential explanations.
Our study had adequate power to detect an association of
diabetes mellitus with long-term cumulative mortality. The
mortality rate was 26% at 48 months after CABG surgery
among diabetics, giving us approximately 80% power to
detect a 35% relative difference or a 9% absolute difference
in mortality at a two-tailed alpha level of 0.05. It is possible
that diabetes does not contribute to the underlying force of
mortality after CABG surgery in ischemic cardiomyopathy
to as large an extent as it does in CAD with preserved
ventricular function. Alternatively, diabetic patients with
ventricular dysfunction may derive a larger benefit from
revascularization of jeopardized myocardium and, therefore,
have similar lifespans as nondiabetics after surgery.
Morbidity findings. Although the risk of death was not
higher for diabetics in our study, diabetes was clearly a risk
factor for morbidity after CABG surgery. There was a
strong association with perioperative complications includ-
ing renal failure, superficial sternal wound infection and use
of mechanical circulatory support. The association with
sternal wound infection is consistent with previous studies
of CABG surgery in diabetic patients (21–25). The associ-
ation between sternal wound infection and epicardial ICD
use in our analysis has been documented in-depth by
Spotnitz and colleagues (19) and may result partly from
reporting bias.
The time to postoperative re-hospitalization was signifi-
cantly shorter for diabetics. The one year re-hospitalization
rate was 54% among diabetics compared with 41% in
nondiabetics. It took almost twice as long for patients in the
nondiabetic group to reach a 50% re-hospitalization rate
compared with those in the diabetic group (44.8 vs. 23.7
months, respectively). Hospitalizations for noncardiac
causes comprised a higher proportion of re-admissions
among diabetics. However, in the context of a much higher
overall re-hospitalization rate, there was a higher relativeTa
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risk of cardiac hospitalization among diabetics, which is
consistent with our second hypothesis regarding excess
morbidity. The implications of our findings for long-term
resource use and costs are significant and have yet to be fully
quantified.
Arrhythmic events. The CABG Patch Trial is the only
study, to our knowledge, of patients after CABG surgery
that has prospectively collected data on ventricular arrhyth-
mias and arrhythmic death during long-term follow-up.
The adjusted risk for arrhythmic death in diabetics was
almost half that in nondiabetics, although with 43 total
arrhythmic deaths, this was not a statistically significant
finding. Arrhythmia was less often the reason for initial
re-hospitalizations after CABG surgery in diabetics, and
substantially fewer ventricular arrhythmias occurred during
hospitalizations in diabetics. Given the past evidence that
has linked autonomic dysfunction with diabetes, we ex-
pected more, not less, arrhythmic events among the diabet-
ics in our study. About 40% of diabetics with and without
ischemic heart disease have cardiac autonomic nerve dys-
function, that is, reduced parasympathetic and increased
sympathetic modulation of RR intervals (7,26,27), and
diabetics with autonomic neuropathy are at increased risk of
death compared with diabetics without autonomic neurop-
athy (28). In addition, prolongation of the QT interval has
been noted in diabetic patients with autonomic neuropathy
(29,30) and ischemic heart disease (31). However, all the
patients in our study had severe LV dysfunction, and the
diabetics had a higher prevalence of heart failure. The
UK-Heart study showed that, among heart failure patients,
reduced heart rate variability was the best predictor of death
due to heart failure but did not predict sudden cardiac death
(32). Ischemic cardiomyopathy may interact with the effect
of diabetes and autonomic neuropathy on arrhythmic
events. Also, diabetics could benefit more from revascular-
ization than nondiabetics, particularly with respect to their
arrhythmic substrate. Further studies are needed to examine
the incidence and significance of ventricular arrhythmias
after CABG surgery in diabetics.
Study limitations. One potential disadvantage of this anal-
ysis is the fact that diabetic patients with poor blood glucose
control or recurrent infections and patients with serum
creatinine .3 mg/dl were excluded from the trial. These
two groups respectively comprised about 0.6% and 0.5% of
the 71,855 screened patients in the enrollment cascade (33).
Thirty-eight percent of the 900 patients in the trial had
diabetes, a larger percentage than most previous observa-
tional studies of CABG surgery. Another limitation of this
study was that the extent of glucose control, in terms of
serum glucose levels or glycosylated hemoglobin levels, was
not available from our database. In addition, the retrospec-
tive nature of our analysis limited the strength of inferences
from the data. However, the multicenter experience pro-
vided by our sample strengthens its generalizability.
Conclusions. Our analysis indicates that diabetes is not a
strong predictor of mortality after CABG surgery among
Table 4. Multivariable Cox Regression Models for Hospitalization
Variable
Hospitalization for Any Reason Hospitalization for Cardiac Reason
Hazard Ratio p Value Hazard Ratio p Value Hazard Ratio p Value Hazard Ratio p Value
Diabetes 1.437 0.0001 — — 1.241 0.0431 — —
Insulin — — 1.598 0.0001 — — 1.224 0.1406
Oral agent/diet — — 1.327 0.0103 — — 1.268 0.0649
Age .65 1.387 0.0002 1.381 0.0002 1.376 0.0019 1.371 0.0021
Stroke 1.940 0.0001 1.933 0.0001 1.698 0.0051 1.690 0.0056
Heart failure 1.134 0.0180 1.130 0.0215 1.201 0.0034 1.198 0.0039
ICD 1.257 0.0083 1.267 0.0064 1.422 0.0007 1.426 0.0006
*There were two separate Cox proportional hazard models for each outcome, one model in which all diabetics were grouped together and another in which patients treated with
insulin and patients treated with oral hypoglycemics or diet were grouped separately.
ICD 5 implantable cardiac defibrillator; — 5 not included.
Table 5. Characteristics of Initial Post-CABG Hospitalizations Among Diabetics
and Nondiabetics*
Diabetes
(n 5 236)
No diabetes
(n 5 324) Odds Ratio p Value
Reason for hospitalization
Arrhythmia (%) 5.5 11.7 0.44 0.017
Other cardiac (%) 37.7 39.8 0.92 0.677
Noncardiac (%) 49.2 39.5 1.48 0.029
Related to ICD (%) 7.6 9.0 0.84 0.687
Cardiac events during hospitalization
Myocardial infarct (%) 2.1 4.0 0.52 0.312
Ventricular arrhythmias (%) 8.6 17.0 0.46 0.007
Heart failure (%) 32.3 31.4 1.05 0.879
*Data were less than the full 560 observations for the following comparisons: ventricular arrhythmias (n 5 533), heart failure
(n 5 557).
ICD 5 implantable cardiac defibrillator.
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patients with LV dysfunction, despite its value as a predictor
of postoperative complications and long-term morbidity.
Further clinical investigations may clarify the long-term
noncardiac risks that diabetics face after CABG surgery and
the effects of CABG surgery on ventricular arrhythmias in
diabetics.
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